What Is kpHMO™? The Science Behind the Most Advanced Human Milk Bioactive

The Question Everyone Is Asking

You've probably heard of probiotics. You may have heard of prebiotics. But human milk oligosaccharides — HMOs — are something else entirely. They're not bacteria. They're not fiber in the traditional sense. They're a structurally unique class of bioactive sugars that evolution spent millions of years perfecting inside human breast milk.

And now, the gut health world is paying attention. Because researchers are discovering that the same molecules that shape a newborn's microbiome may offer transformative benefits for adult gut health too.

So what exactly is kpHMO™? And why is it the most advanced human milk bioactive available today?

Let's start at the beginning.

What Are Human Milk Oligosaccharides?

Human milk oligosaccharides are complex carbohydrates found naturally in human breast milk. In terms of quantity, they are the third most abundant solid component of human milk — present at concentrations of 5–20 grams per liter, exceeded only by fat and lactose.

Here's what makes them remarkable: the human infant cannot actually digest HMOs. They pass through the stomach and small intestine essentially intact, arriving in the colon where they serve as selective food for beneficial bacteria — particularly Bifidobacterium species that are critical for early-life immunity, digestion, and brain development.

But their role doesn't stop at feeding bacteria. HMOs also bind directly to epithelial cells and immune receptors in the gut lining, acting as decoy receptors that may block pathogens from attaching to the gut wall. They may modulate immune cell signaling. They help maintain the integrity of the intestinal barrier. In short, HMOs are gut architects.

Human milk contains over 200 distinct HMO structures. They fall into three main chemical categories based on their architecture:

• Neutral HMOs — the structural backbone; abundant and bifidogenic
• Fucosylated HMOs — decorated with fucose sugars; prominent in pathogen blocking and immune modulation
• Sialylated HMOs — carrying sialic acid; important for brain development and immune signaling

Nature didn't evolve just one or two of these structures. It evolved all three families working in concert. That full-spectrum complexity is the key insight behind kpHMO™.

Why HMO Complexity Matters — The Spectrum Problem

When the supplement industry first began manufacturing HMOs, they logically started with the most abundant ones. A single HMO that's easy to produce at scale can be tested, standardized, and sold.

But there's a fundamental problem with that approach.

A landmark 2023 clinical study published in Scientific Reports by Jacobs et al. gave 32 healthy adults a full-spectrum HMO concentrate derived from pooled donor breast milk over 7 days. The results showed dose-dependent Bifidobacterium expansion, increased levels of the anti-inflammatory cytokines TGFβ and IL-10, and meaningful changes to the microbiome that persisted through day 28 after supplementation ended. [PMID: 37652940]

The researchers then did something critical: they tried to replicate these results using a defined mixture of the 10 most abundant individual HMOs in the concentrate — at their exact measured concentrations. The individual and blended single-HMO approach did not replicate the same microbiome shifts.

The conclusion? Complex mixtures — including low-abundance HMO structures — may be required for maximum effect. The full orchestra produces something that individual instruments cannot.

This is why HMO complexity matters. And it's the scientific foundation behind kpHMO™.

Introducing kpHMO™: The Proprietary Ingredient at the Core of kēpos

kpHMO™ is kēpos's proprietary human milk bioactive ingredient — engineered to best replicate the oligosaccharide composition found in actual breast milk. It is not a single HMO. It is not a simple combination of two or three well-known structures. It is a carefully developed proprietary ingredient that covers all neutral, fucosylated, and sialylated HMO bases — mirroring the molecular breadth that nature placed in human milk for a reason.

Think of it this way: breast milk doesn't contain just one HMO structure any more than your gut contains just one type of bacteria. Diversity and complexity are features, not accidents. kpHMO™ is built on that principle.

What sets kpHMO™ apart from typical single-HMO supplements on the market:

• Full-spectrum design — covers neutral, fucosylated, and sialylated HMO categories, just as human milk does
• Proprietary formulation — not a generic off-the-shelf ingredient; developed specifically to match the complexity of breast milk oligosaccharides
• Scientifically grounded — developed in light of emerging research showing that HMO complexity drives outcomes that single structures cannot
• Unique differentiator — unavailable in any other adult supplement on the market

When you take kēpos, you're not getting one HMO. You're getting the most advanced human milk bioactive ingredient available, formulated to do what nature intended HMOs to do: nourish, protect, and support the adult gut at a molecular level.

What the Science Shows About HMOs in Adults

For a long time, HMO research focused almost exclusively on infants. But the tide has shifted dramatically. Here's what clinical and translational research now shows about HMOs in adult gut health:

HMOs Support a Healthier Gut Barrier

A foundational study by Šuligoj, Vigsnæs, Van den Abbeele and colleagues published in Nutrients used the SHIME® gut simulation system alongside human intestinal Caco2 cells and gut-on-chip organoid models. HMOs — particularly 2'-FL — significantly reduced intestinal permeability, upregulated the tight junction protein claudin-8, and reduced the pro-inflammatory cytokine IL-6 in intestinal cells. [PMID: 32933181]

A less permeable, more resilient gut wall means fewer undigested food particles and microbial toxins crossing into the bloodstream — a phenomenon increasingly linked to systemic inflammation.

HMOs Selectively Feed Beneficial Bacteria

In a 2024 ex vivo study by Bajic, Wiens, Wintergerst and colleagues, four different HMO structures were applied to cultured fecal microbiota from children and adults at doses ranging from 0.3 to 5 grams per day equivalent. HMOs significantly increased short-chain fatty acid (SCFA) production — including butyrate, propionate, and acetate — starting from doses as low as 0.3–0.5 g/day. Bifidobacteriaceae increased significantly at the lowest doses tested. [PMID: 38668367]

SCFAs matter because they are the primary fuel for colonocytes (the cells lining your colon), play a role in immune regulation, and are associated with reduced gut inflammation.

HMOs May Support Gut Health in IBS

A Phase II randomized controlled trial in 58 adults with irritable bowel syndrome (IBS) found that HMO supplementation over four weeks increased Bifidobacterium adolescentis and Bifidobacterium longum, and modulated fecal and plasma metabolite profiles in ways linked to changes in the gut microenvironment. The researchers concluded that these findings support the assertion that HMO supplementation modulates the intestinal microenvironment of IBS patients. [PMID: 34836092]

For anyone who's experienced the unpredictability of IBS and wondered whether gut-targeted interventions can actually reach the root — this data is meaningful.

HMOs May Modulate Immune Signaling

The Jacobs et al. 2023 clinical trial (32 healthy adults, 7-day dosing) found that a complex HMO mixture increased circulating levels of TGFβ and IL-10 — two cytokines associated with immune regulation and the suppression of excessive inflammatory signaling. [PMID: 37652940] This anti-inflammatory immune signal adds another dimension to the way HMOs may support adult health beyond the gut alone.

How kpHMO™ Compares to Single-HMO Supplements

The HMO supplement market is growing rapidly, but most products contain only one or two isolated HMO structures — the ones that happen to be easiest and cheapest to produce at scale. There's nothing wrong with studying these structures individually. But when you compare them against a full-spectrum HMO approach, the difference in mechanism is meaningful.

Here's how kpHMO™ stands apart:

• Single-HMO supplements target the microbiome through one molecular pathway. kpHMO™ engages multiple HMO families — neutral, fucosylated, and sialylated — simultaneously.
• The Jacobs et al. clinical data showed that the top-10 most abundant individual HMOs, when mixed, failed to replicate the microbiome effects seen with a complex full-spectrum concentrate. Breadth matters.
• Different HMO structures appear to have distinct functional roles: fucosylated HMOs are linked to pathogen-binding, sialylated HMOs to immune signaling, neutral HMOs to bifidogenic activity. A full-spectrum ingredient doesn't force you to choose.

kpHMO™ was designed with this science in mind. It is not a shortcut to market. It is a serious attempt to bring what human milk actually delivers — in full complexity — to an adult supplement.

kēpos: The Only Supplement Pairing kpHMO™ with effera™

Human milk doesn't only contain HMOs. One of its other major bioactive components is lactoferrin — an iron-binding glycoprotein that supports immune function, iron absorption, and gut barrier integrity.

Most lactoferrin supplements on the market are derived from bovine (cow) milk. Human lactoferrin and bovine lactoferrin differ in structure and receptor affinity, with human lactoferrin showing different binding characteristics that may be more relevant to human physiology.

kēpos features effera™ — a recombinant human lactoferrin (rhLF). Not bovine. Not approximated. The same molecular structure as the lactoferrin found in human milk, produced through precision fermentation.

The combination of kpHMO™ and effera™ in kēpos is not arbitrary. It mirrors the way breast milk delivers its most powerful gut-protective bioactives together. HMOs shape the microbiome and reinforce the gut barrier. Lactoferrin modulates iron metabolism and supports immune defense. Together, they may support a more comprehensive gut health outcome than either ingredient alone.

No other supplement on the market offers this pairing. That's not marketing. That's just the current state of the category.

What This Means for Your Gut Health

If you've been cycling through probiotics, fiber supplements, and digestive enzymes without feeling that you've truly addressed the root of your gut issues — kpHMO™ represents a fundamentally different approach.

Probiotics add bacteria. HMOs change the environment that bacteria live in. There's a significant difference. A probiotic can introduce a beneficial strain, but if your gut environment doesn't favor it, that strain won't survive or thrive. HMOs work upstream — by selectively feeding the bacteria that are already there and maintaining the structural integrity of the gut itself.

This is next-generation gut health science. And kpHMO™ is built to deliver it.

→ Learn more about kēpos and explore what kpHMO™ + effera™ can do for your gut

---

Frequently Asked Questions About kpHMO™

---

Written by Oliver Drazsky | kēpos Gut Health Research Team

All claims are supported by peer-reviewed research. References linked throughout. For a full list of verified citations, see PMIDs: 32933181, 34836092, 37652940, 38668367.